Assay of Some Thromboplastin Generation Factors^[*]

Summary

A method for measuring six plasma or serum factors required for intrinsic thromboplastin formation is described by which various dilutions of normal serum are used to correct the abnormal TGT obtained with specifically deficient blood. When the arithmetic product of the minimum clotting time and the corresponding incubation time are plotted against the logarithm of the concentration of the particular factor in question, a rectilinear relationship is obtained for factors V, VIII, IX, XI and XII, and a hitherto unrecognized new serum factor (Thorium Vulnerable Factor, TVF). This correlation does not hold for factor X. Thus far no mathematical or biochemical equation could be formulated to explain the empiric observations.

Other reported assay procedures are discussed.

• References

• 1 Progress in Coagulation. Transactions of International Committee on Blood Coagulation Factors. List of Synonyms. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 5, p. 379, 1962
• 2 Alexander B, Kliman A, Colman R, Scholtz E, Di Francesco A. New “Hemophilioid” Defects. Some Clinicolaboratory and experimental abnormalities in Thromboplastin Generation. Symposium on Hemophilia and Other Hemorrhagic States. K. Brinkhous, Ed., Univ. of North Carolina, p. 137, 1959
• 3 Alexander B, Colman R. Evidence for a new serum thromboplastin factor.. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 1: 66 1960;
• 4 Colman R, Alexander B. The effect of lanthanides and actinides on blood coagulation. I. Evidence for and properties of a new serum thromboplastin factor. J. clin. Invest. 43: 705 1964;
• 5 Colman R, Alexander B. The effect of lanthanides and actinides on blood coagulation. II. Assay of a new serum thromboplastic factor vulnerable to these elements and its variations in health and disease. J. clin. Invest. 43: 120 1964;
• 6 Biggs R, Douglas A. S. Thromboplastin generation test. J. clin. Path. 6: 23 1953;
• 7 Hougie C, Barrow E. M, Graham J. B. Stuart clotting defect. I. Segregation of a hereditary hemorrhagic state from the heterogeneous group heretofore called “stable factor” (SPCA), proconvertin, (Factor VII) deficiency. J. clin. Invest. 36: 485 1957;
• 8 Rosenthal R. L, Dreskin O. H, Rosenthal N. New hemophilia-like disease caused by the deficiency of third plasma thromboplastin factor. Proc. Soc. exper. Biol. 82: 71 1953;
• 9 Ratnoff O. D, Colopy J. E. Familial hemorrhagic trait associated with deficiency of clot promoting fraction of plasma. J. clin. Invest 34: 602 1955;
• 10 Owren P. A, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest. 3: 201 1951;
• 11 Bachmann F, Duckert F, Koller F. Stuart-Prower factor assay and its clinical significance. Thrombos. Diathes. haemorrh. (Stuttg.) 2: 24 1958;
• 12 Rappaport S. L, Proctor R. B, Patch M. S, Yettra M. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 18: 149 1961;
• 13 Rodman N. F, Barrow E. M, Graham J. B. Diagnosis and control of the hemophilioid states with the partial thromboplastin time (PTT) test. Amer. J. clin. Path. 29: 525 1958;
• 14 Alexander B, Landwehr G. Studies of hemophilia. II. The assay of antihemophilic clot-promoting principle in normal human plasma with some observations on the relative potency of certain plasma fractions. J. clin. Invest. 27: 98 1948;
• 15 Biggs R, Macfarlane R. G. Haemophilia and related conditions. Brit. J.Haemat. 4: 1 1958;
• 16 Graham J. B, Collins Jr. D. L, Goodwin I. D, Brinkhous K. M. Assay of antihemophilic activity in normal heterozygous (hemophilia) and prothrombopenic dogs. Proc. Soc. exper. Biol. 77: 294 1951;
• 17 Lewis J. H, Ferguson J. H, Fresh J. W, Zucker M. B. Primary hemorrhagic disease. J. Lab. clin. Med. 49: 211 1961;
• 18 Langdell R. D, Wagner R. H, Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests. J. Lab. clin. Med. 41: 637 1953;
• 19 Barrow E. M, Bullock W. R, Graham J. B. A study of the carrier state for plasma thromboplastin component (PTC, Christmas Factor) deficiency utilizing a new assay procedure. J. Lab. clin. Med. 55: 936 1960;
• 20 Duckert F. The prephase accelerator: present status. Thrombos. Diathes. haemorrh. (Stuttg.) 5: 254 1961;
• 21 Biggs R, Eveling J, Richards G. The assay of antihemophilic globulin activity. Brit. J. Haemat. I: 26 1955;
• 22 Pitney W. R. The assay of antihemophilic globulin (AHG) in plasma. Brit. J. Haemat. 2: 250 1956;
• 23 Biggs R, Macfarlane R. G. Human blood coagulation and its disorders. 2nd Ed.. Oxford; Blackwell Scientific Publications: 1957
• 24 Pool J. G, Robinson J. Assay of Plasma antihemophilic globulin (AHG). Brit. J. Haemat. 5: 17 1959;
• 25 Bolton F. G, Clarke J. E. A method of assaying Christmas Factor; its application to the study of Christmas Disease (Factor IX Deficiency). Brit. J. Haemat. 5: 396 1959;
• 26 McMillan C. W, Diamond L. K, Surgenor D. M. The use of fibrinogen rich in Factor VIII for hemorrhage and for surgery. New Engl. J. Med. 265: 224 1961;
• 27 Surgenor D. M, McMillan C. W, Diamond L. K, Steele B. B. Studies with AHF-rich fibrinogen in classical hemophilia. Vox Sang. 5: 80 1960;
• 28 McMillan C. W. XVI Scientific Meeting of the Protein Foundation, Boston. Vox Sang. Sep. Vol. 7, No. 1, p. 96, 1961
• 29 Macfarlane R. G, Biggs R. Hemophilia and other hemorrhagic states. 19 Univ. of North Carolina Press; Chapel Hill, N. C.: 1959
• 30 Fisch U, Duckert F. Some Aspects of Kinetics of the First Stages of Blood Thromboplastin Formation. Thrombos. Diathes. haemorrh. (Stuttg.) 3: 98 1959;
• 31 Johnson C. L, Ferguson J. H, O’Hanlan F, Black W. L. The fate of Factor VII and Stuart Factor during the clotting of normal blood. Thrombos. Diathes. haemorrh. (Stuttg.) 3: 367 1959;
• 32 Lewis J. H, Didisheim P, Ferguson J. H, Dalton K. Changes occurring during coagulation in glass. I. Normal human blood. Thrombos. Diathes. haemorrh. (Stuttg.) 4: 1 1960;